Florida Financial Advisors LLC Takes $229,000 Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Florida Financial Advisors LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel.com reports. The fund bought 688 shares of the company’s stock, valued at approximately $229,000.

Several other hedge funds have also recently added to or reduced their stakes in MEDP. Pallas Capital Advisors LLC increased its position in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Barclays PLC grew its stake in shares of Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC increased its holdings in Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after buying an additional 844 shares during the last quarter. Janus Henderson Group PLC raised its stake in Medpace by 10.0% in the third quarter. Janus Henderson Group PLC now owns 44,118 shares of the company’s stock valued at $14,722,000 after buying an additional 4,023 shares in the last quarter. Finally, SYM FINANCIAL Corp purchased a new stake in Medpace during the 4th quarter worth about $320,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP opened at $324.51 on Wednesday. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The firm has a 50-day simple moving average of $337.16 and a 200-day simple moving average of $339.57. The company has a market capitalization of $9.89 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on MEDP shares. Leerink Partners started coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 price objective on the stock. Leerink Partnrs raised shares of Medpace to a “hold” rating in a report on Monday. Finally, Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.